Las células T del sistema inmunológico han sido reprogramadas en memoria regenerativa similar a las células madre (TSCM) células que son de larga vida, altamente activo “células súper inmunes” con fuerte actividad antitumoral, según una nueva investigación del Centro Integral del Cáncer Georgetown Lombardi.
The reprogramming involves a novel approach the researchers developed that inhibits the activity of proteins known as MEK1/2. Actualmente, several MEK inhibitors are used to effectively treat melanoma, but this study demonstrates that MEK inhibitors don’t just target certain types of cancer cells, but rather, more broadly, reprogram T cells to fight many types of cancer.
The finding appears November 23, 2020, enNature Immunology.
“Although immunotherapies have improved survival for cancer patients over recent years, survival rates remain sub-optimal. Por lo tanto, there is an urgent need to develop novel, more effective anti-cancer immunotherapies,” says Samir N. Khleif, Maryland, director of The Jeannie and Tony Loop Immuno-Oncology Laboratory and head of the team that conducted this research. “Our research shows that using drugs that have already been approved for human use may significantly enhance currently available immune therapeutic approaches, thereby leading to better and more durable anti-cancer responses.”
